BD HorizonTM RB780 Mouse Anti-Human LAG-3 (CD223)

Description

Multicolor flow cytometric analysis of LAG-3 CD223 expression on Unstimulated Top Plots and Stimulated Bottom Plots Human peripheral blood lymphocytes. Human peripheral blood mononuclear cells PBMC were cultured for 3 days with plate-bound Anti-Human CD3 Cat. No. 567109/567108/555329; 10 mug/ml for coating and soluble Anti-Human CD28 Cat. No. 555725; 1 mug/ml antibodies, and Recombinant Human IL-2 Protein Cat. No. 554603; 10 ng/ml . Unstimulated PBMC from the same donor and Stimulated PBMC were stained with BD Horizon BV421 Mouse Anti-Human CD8 Cat. No. 562428/562429; Left Plots , BD Horizon R718 Mouse Anti-Human CD279 PD-1 Cat. No. 566974/566975; Right Plots , and BD Horizon RB780 Mouse Anti-Human LAG-3 CD223 Cat. No. 569094/569095 antibodies. BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. Bivariate pseudocolor density plots showing the correlated expression of LAG-3 CD223 versus CD8, or LAG-3 CD223 versus CD279 PD-1 were derived from gated events with the forward and side-light scatter characteristics of viable 7-AAD-negative unstimulated or stimulated lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. Multicolor flow cytometric analysis of LAG-3 CD223 expression on Unstimulated Top Plots and Stimulated Bottom Plots Human peripheral blood lymphocytes. Human peripheral blood mononuclear cells PBMC were cultured for 3 days with plate-bound Anti-Human CD3 Cat. No. 567109/567108/555329; 10 mug/ml for coating and soluble Anti-Human CD28 Cat. No. 555725; 1 mug/ml antibodies, and Recombinant Human IL-2 Protein Cat. No. 554603; 10 ng/ml . Unstimulated PBMC from the same donor and Stimulated PBMC were stained with BD Horizon BV421 Mouse Anti-Human CD8 Cat. No. 562428/562429; Left Plots , BD Horizon R718 Mouse Anti-Human CD279 PD-1 Cat. No. 566974/566975; Right Plots , and BD Horizon RB780 Mouse Anti-Human LAG-3 CD223 Cat. No. 569094/569095 antibodies. BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. Bivariate pseudocolor density plots showing the correlated expression of LAG-3 CD223 versus CD8, or LAG-3 CD223 versus CD279 PD-1 were derived from gated events with the forward and side-light scatter characteristics of viable 7-AAD-negative unstimulated or stimulated lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software. Show More Multicolor flow cytometric analysis of LAG-3 CD223 expression on Unstimulated Top Plots and Stimulated Bottom Plots Human peripheral blood lymphocytes. Human peripheral blood mononuclear cells PBMC were cultured for 3 days with plate-bound Anti-Human CD3 Cat. No. 567109/567108/555329; 10 mug/ml for coating and soluble Anti-Human CD28 Cat. No. 555725; 1 mug/ml antibodies, and Recombinant Human IL-2 Protein Cat. No. 554603; 10 ng/ml . Unstimulated PBMC from the same donor and Stimulated PBMC were stained with BD Horizon BV421 Mouse Anti-Human CD8 Cat. No. 562428/562429; Left Plots , BD Horizon R718 Mouse Anti-Human CD279 PD-1 Cat. No. 566974/566975; Right Plots , and BD Horizon RB780 Mouse Anti-Human LAG-3 CD223 Cat. No. 569094/569095 antibodies. BD Via-Probe Cell Viability 7-AAD Solution Cat. No. 555815/555816 was added to cells right before analysis. Bivariate pseudocolor density plots showing the correlated expression of LAG-3 CD223 versus CD8, or LAG-3 CD223 versus CD279 PD-1 were derived from gated events with the forward and side-light scatter characteristics of viable 7-AAD-negative unstimulated or stimulated lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo software.